RxDoctor Payments Data

Steven Schneider, MD

Obstetrics & Gynecology · Wakefield, RINPI 1063421659

Payments from drug & device makers

What this record shows

This record is dominated by other: $3,000 of the $4,948 with a category attached, or 60.6%. Intuitive Surgical accounts for 61.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $3,115 and has fallen 95.6% since, to $136 in 2025.

$4,948in general payments, 2019–2025

Across 69 payments — averaging $71.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Covidien LP$550
  • AbbVie$320
  • Astellas Pharma US Inc$313
  • Bayer$184
  • Pfizer$64
  • plus $499 from 15 others

What the payments were for

  • Consulting fees$55011%
  • Food & beverage$1,37428%
  • Education$240%
  • Other$3,00061%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,948 in reported general payments places this provider in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.

See all obstetrics & gynecology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,263
Medicare patients
127
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron35$20,194
Estradiol126$7,518
VeozahFezolinetant11$5,608
PremproEstrogen,con/M-Progest Acet11$3,062
YuvafemEstradiol27$2,902
Oxybutynin Chloride ErOxybutynin Chloride41$959
Estradiol (Twice Weekly)Estradiol13$892
ValacyclovirValacyclovir Hcl23$874
Alendronate Sodium47$427
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet13$426
Clobetasol Propionate17$287
Fluconazole26$284
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$260
Solifenacin Succinate15$233
Acyclovir12$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Veozah$313$25,80246 claims
PfizerPrempro$64$3,06211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.

Other obstetrics & gynecology in Wakefield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →